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Abstract: Here we report methods of preparation for liposome formulations containing lipophilic drugs.
In contrast to the encapsulation of water soluble compounds into the entrapped aqueous volume of
a liposome, drugs with lipophilic properties are incorporated into the phospholipid bilayer membrane.
Water-soluble molecules, for example cytotoxic or antiviral nucleosides can be transformed into lipophilic
compounds by attachment of long alkyl chains, allowing their stable incorporation into liposome mem-
branes and taking advantage of the high loading capacity lipid bilayers provide for lipophilic molecules.
We created a new class of cytotoxic drugs by chemical transformation of the hydrophilic drugs cytosine-
arabinoside (ara-C), 5-fluoro-deoxyuridine (5-FdU), and ethinylcytidine (ETC) into lipophilic compounds
and their formulation in liposomes.The concept of chemical modification of water-soluble molecules by
attachment of long alkyl chains and their stable incorporation into liposome bilayer membranes represent
a very promising method for the development of new drugs not only for the treatment of tumors or
infections but also for many other diseases.
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5­fluoro­deoxyuridine  (5­FdU),  and  ethinylcytidine  (ETC)  into  lipophilic  compounds  and  their
formulation in liposomes.
The concept of chemical modification of water­soluble molecules by attachment of long alkyl chains and
their  stable  incorporation  into  liposome  bilayer membranes  represent  a  very  promising method  for  the








































































N ­octadecyl­1­β­老‰­arabinofuranosylcytosine,  mol.  wt.  801  g/mol),  5­FdU­NOAC  (2′­deoxy­5­
fluorouridylyl­(5′  →  5′)­N ­octadecyl­1­β­老‰­arabinofuranosylcytosine,  mol.  wt.  804  g/mol)  and  ETC­

























4. Phosphate buffer, PB (13 mM KH PO , 54 mM NaHPO , pH 7.4) (see Note 3  ).
5. Round bottom flasks (20–100 ml).
6. Rotatory evaporator, e.g., Rotavap (Büchi AG, Flawil, Switzerland).
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